Research programme: AMPK activators - NovaTarg Therapeutics

Drug Profile

Research programme: AMPK activators - NovaTarg Therapeutics

Alternative Names: NT 1044

Latest Information Update: 09 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NovaTarg Therapeutics
  • Class Antineoplastics; Biguanides
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Hepatitis C
  • Research Dengue; Fatty liver; Polycystic kidney disease; Type 2 diabetes mellitus

Most Recent Events

  • 25 May 2016 Early research in Fatty liver and Dengue in USA (unspecified route) (Novatarg Therapeutics website, May 2016)
  • 25 May 2016 Preclinical trials in Hepatitis C and Cancer in USA (unspecified route) (Novatarg Therapeutics website, May 2016)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top